Dupixent, Sanofi

In 2022, Sanofi’s adherence to its strategy has yielded an expanded pipeline, greater sales and net income, and progress in the use of artificial intelligence.

Entyvio, Takeda

Takeda’s top five brands all grew substantially in FY 2022, none by less than 30 percent.

Med Ad News, October 2023

For this 37th annual special report, Med Ad News editors rank the world’s top 50 companies that generate revenue from prescription medicines and healthcare products.

The FDA on Monday denied approval of Alnylam Pharmaceuticals’ siRNA therapy Onpattro (patisiran) for the treatment of cardiomyopathy of transthyretin-mediated amyloidosis.

BMS, Bristol Myers Squibb

Bristol Myers Squibb on Sunday announced that it has entered into a definitive merger agreement with cancer-focused biotech Mirati Therapeutics in a bid to grow its oncology franchise.

Novartis, California

The FDA on Friday approved an intravenous formulation of Novartis’ IL-17A antagonist Cosentyx (secukinumab) for the treatment of rheumatic diseases.

The Bill & Melinda Gates Foundation will give $40 million, including to a Belgian biotech company and two leading African vaccine manufacturers, in a bid to boost access to mRNA vaccines for protection against various diseases in Africa.

Merck on Thursday reported that its blockbuster PD-1 inhibitor Keytruda (pembrolizumab) met one of its dual primary endpoints in the Phase III AMBASSADOR trial in muscle-invasive urothelial carcinoma.

Dengue fever will become a major threat in the southern United States, southern Europe and new parts of Africa this decade, the WHO’s chief scientist said, as warmer temperatures create the conditions for the mosquitoes carrying the infection to spread.

FDA

The FDA has placed a partial clinical hold on two of Innate Pharma’s trials assessing its investigational antibody lacutamab following one patient death, the company announced Thursday